South San Francisco, CA -- July 3, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III...

MONDAY, July 1, 2024 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved...

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat...

Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line...

The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC...

SYDNEY, July 10, 2024. Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a...

TUESDAY, July 9, 2024 -- Intensity-modulated radiotherapy (IMRT) is recommended for locally advanced non-small cell lung cancer (NSCLC) and appears...

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise...

Updated Date: Fri, 12 Jul 2024 00:00:00 EDT

Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in...